Click main image to view in full screen.
BENEFITS OF DOCUMENT
- Colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025
- Etiology and Pathophysiology
- Market Overview
DESCRIPTION
The colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025 in the seven major pharmaceutical markets under study. Growth will be fueled by continued uptake of premium-priced therapies and the approval of six emerging therapies. In 2025, immune checkpoint inhibitors will hold an impressive 33% share of this market.
Two immune checkpoint inhibitors are expected to launch for colorectal cancer (Merck & Co.'s Keytruda [pembrolizumab] and Roche/Genentech/Chugai's Tecentriq [atezolizumab]), significantly contributing to the aforementioned market growth. Their combined major-market sales will total approximately $4.2 billion in 2025, driven largely by the two agents: approval in MSI-H and dMMR patient populations.
Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?
Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.
Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Colorectal Cancer PDF (PDF) Document, pharmzolgas
